“441”, known as “GS441524”, is a nucleoside analog of ridecivir developed by the American pharmaceutical company Gilead.
In 2012, Dr. Pedersen, a leading professor at the University of California, Davis, after 50 years of research on feline infectious peritonitis (FIP), confirmed for the first time that the FIPV virus is a mutation of the coronavirus FeCV.
After identifying the source of the virus, Dr. Pedersen suggested that RNA virus-targeting inhibitors used to treat SARS and MERS in humans might be effective in treating feline infectious peritonitis, a fatal disease of cats.
In 2017, Dr. Pedersen obtained GS441524, a nucleoside analog of raltegravir, from Gilead for the treatment of feline infectious peritonitis. After 12 weeks of treatment of 31 affected cats, 25 cats recovered.
On September 20, 2018, Gilead successfully registered the patent for GS441524 However, the company declined to submit an application for GS441524 to the FDA due to the company’s focus on Ebola as its primary research target and its commitment to the launch of raltegravir, as well as the fact that Gilead does not have a veterinary division and is not interested in producing animal drugs.
Although the genuine GS441524 is not yet on the market, its formulation is publicly available, which has led to the emergence of several generic drugs in the country. Regardless of the brand or manufacturer, these are all generic drugs.
Original article by KPTer, if reproduced, please cite the source: https://www.kaipet.com/en/441-effective-drug-feline-infectious-peritonitis